Osteoporosis Silently Fractures Women's Lives — Here's What Clinicians Miss

Osteoporosis is one of the most prevalent yet underappreciated threats to healthy aging, particularly for postmenopausal women. Despite centuries of documented history and decades of established clinical guidelines, it remains dramatically underdiagnosed — often discovered only after a fragility fracture has already occurred. This StatPearls review synthesizes current knowledge on the condition's pathophysiology, epidemiology, screening, and treatment to address persistent gaps in clinical practice.

The condition is defined by low bone mineral density and microarchitectural deterioration of bone tissue, which together dramatically increase fracture risk. Fractures — especially of the hip, spine, and wrist — can trigger cascading health consequences including chronic pain, disability, loss of independence, and premature death. The disease affects both sexes but is far more prevalent in women, particularly after menopause, when estrogen decline accelerates bone loss.

Historically, American endocrinologist Fuller Albright established the link between ovarian function loss and vertebral fracture risk in 1941, and showed that estrogen replacement could reverse this effect. This foundational work underpins our modern understanding of postmenopausal bone loss and hormone-related interventions. Current treatment options include bisphosphonates, RANKL inhibitors, and anabolic agents, alongside calcium, vitamin D, and lifestyle modifications.

Despite available tools, the review highlights a troubling reality: education and awareness about osteoporosis screening remain substandard even among healthcare providers, leading to systematic underdiagnosis. Screening via dual-energy X-ray absorptiometry (DEXA) is recommended for women aged 65 and older, or younger postmenopausal women with risk factors, yet uptake remains inadequate.

With global populations aging, the incidence of osteoporosis is projected to increase exponentially. Closing the gap between guideline recommendations and real-world practice — through better clinician education, routine screening, and earlier intervention — is essential to reducing the enormous personal and societal burden of this silent epidemic.